Sacubitril/Valsartan: A Modern Medicine for Heart Failure

Sacubitril/Valsartan: A Modern Medicine for Heart Failure

Heart failure is a condition where the heart cannot pump enough blood to meet the body’s needs. This can cause tiredness, shortness of breath, and swelling in the legs. Sacubitril/Valsartan is a medicine that helps the heart work better and reduces the risk of hospitalization and death in people with heart failure.

What is Sacubitril/Valsartan?

Sacubitril/Valsartan is a combination medicine that contains two drugs:

  • Sacubitril helps relax blood vessels and removes extra salt and water from the body.
  • Valsartan lowers blood pressure by blocking a hormone that narrows blood vessels.

Together, they reduce the workload on the heart and improve blood flow.

Uses

Sacubitril/Valsartan is used to:

  • Treat heart failure with reduced ejection fraction (HFrEF).
  • Reduce the risk of hospitalization due to heart failure.
  • Lower the risk of death from heart-related problems.

Common Side Effects

Some people may experience:

  • Low blood pressure
  • Dizziness
  • High potassium levels
  • Kidney problems
  • Cough

A rare but serious side effect is angioedema, which causes swelling of the face, lips, tongue, or throat. This needs immediate medical attention.

Drug Interactions

Sacubitril/Valsartan may interact with:

  • ACE inhibitors (such as enalapril) – Do not take them together.
  • Potassium supplements – May increase potassium levels.
  • NSAIDs (such as ibuprofen) – May affect kidney function.
  • Lithium – May increase the risk of lithium toxicity.

Always tell your doctor about all the medicines you are taking.

Conclusion

Sacubitril/Valsartan is an effective medicine for treating heart failure. It helps the heart pump blood more efficiently, reduces hospital visits, and improves survival. It should only be taken under a doctor’s supervision, with regular monitoring for safety.

MBH/PS

1 Like

Switching eligible HFrEF patients from conventional ACE inhibitors or ARBs to Sacubitril/Valsartan has fundamentally reshaped guideline-directed medical therapy (GDMT). By promoting vasodilation and natriuresis while simultaneously halting adverse cardiac remodeling, it directly targets both symptom burden and long-term disease progression.

Informative post! I like the way how you explained everything in detail.